Table 2 G6PD activity and genotypes according to the different clinical groups

Group 1. Hospitalization during neonatal period n = 9

G6PD A^−202A/376G

4/49

3 (1.55–4.60)

34.1 (17.42–51.66)

G6PD A^−376G/968C

3/18

1.6 (1.2–2.0)

17.6 (13.48–22.47)

G6PD A^−202A/376G (Heterozygous female)

1/1

0.35

3.93

Mediterranean

1/1

0.10

1.12

Average (min-max)

1.92 (0.10–4.60)

21.60 (1.12–51.69)

Group 2. NNJ non-hospitalized, n = 38

G6PD A^−202A/376G

21/49

2.9 (1.10–4.10)

32 (12.36–46.07)

G6PD A^−376G/968C

10/18

1.4 (0.50–2.33)

15.9 (5.62–26.22)

Union-Maewo

3/6

0.1 (0.05–0.10)

0.8 (0.78–1.12)

Akrokorinthos

1/1

2.7

29.8

Santamaria

1/1

0.9

10.1

Mahidol

1/1

2.7

30.3

Viangchan-Jammu

1/1

3.9

43.8

Average (min-max)

2.22 (0.10–4.10)

24.97 (1.12–46.07)

Group 3. Asymptomatic during the neonatal period, n = 34

G6PD A^−202A/376G

24/49

2.6 (1.40–4.80)

29.6 (15.73–53.93)

G6PD A^−376G/968C

5/18

1.8 (1.20–2.60)

20.1 (13.48–29.21)

Union-Maewo

3/6

0.1 (0.05–0.06)

0.6 (0.56–0.67)

Akrokorinthos

1/1

4.0

44.9

Belem

1/1

1.1

12.4

Average (min-max)

2.28 (0.05–4.8)

25.62 (0.56–53.93)